NO20083868L - IAP BIR domenebindende forbindelser - Google Patents
IAP BIR domenebindende forbindelserInfo
- Publication number
- NO20083868L NO20083868L NO20083868A NO20083868A NO20083868L NO 20083868 L NO20083868 L NO 20083868L NO 20083868 A NO20083868 A NO 20083868A NO 20083868 A NO20083868 A NO 20083868A NO 20083868 L NO20083868 L NO 20083868L
- Authority
- NO
- Norway
- Prior art keywords
- iap
- bes
- domain
- binding connections
- connections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78252306P | 2006-03-16 | 2006-03-16 | |
US87699406P | 2006-12-26 | 2006-12-26 | |
PCT/CA2007/000428 WO2007104162A1 (en) | 2006-03-16 | 2007-03-16 | Iap bir domain binding compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083868L true NO20083868L (no) | 2008-11-06 |
Family
ID=38509005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083868A NO20083868L (no) | 2006-03-16 | 2008-09-09 | IAP BIR domenebindende forbindelser |
Country Status (15)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006020060A2 (en) | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
AU2006216450C1 (en) * | 2005-02-25 | 2013-01-10 | Medivir Ab | Dimeric IAP inhibitors |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
EP1973899A4 (en) | 2005-12-19 | 2010-10-20 | Genentech Inc | HEMMER OF IAP |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
JP2009530424A (ja) * | 2006-03-21 | 2009-08-27 | ジョイアント ファーマスーティカルズ、インク. | 小分子アポトーシスプロモーター |
MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
CL2007002167A1 (es) * | 2006-07-24 | 2009-01-23 | Tetralogic Pharm Corp | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
JP5452223B2 (ja) * | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Iap阻害剤 |
AU2008240153B2 (en) * | 2007-04-12 | 2013-01-31 | Joyant Pharmaceuticals, Inc. | SMAC mimetic dimers and trimers useful as anti-cancer agents |
WO2008134679A1 (en) * | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
US20110008802A1 (en) * | 2007-05-07 | 2011-01-13 | Tetralogic Pharmaceuticals Corp. | TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
NZ588652A (en) | 2008-04-23 | 2012-09-28 | Rigel Pharmaceuticals Inc | Carboxamide compounds for the treatment of metabolic disorders |
US20110117081A1 (en) * | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
CA2728933A1 (en) * | 2008-06-27 | 2009-12-30 | Aegera Therapeutics Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
AU2009279924B2 (en) * | 2008-08-02 | 2014-10-02 | Genentech, Inc. | Inhibitors of IAP |
WO2010015090A1 (en) * | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
US20110177060A1 (en) * | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
US8283372B2 (en) * | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
US8551955B2 (en) * | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
KR20120140658A (ko) | 2010-02-12 | 2012-12-31 | 파마사이언스 인크. | Iap bir 도메인 결합 화합물 |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
CA2916970A1 (en) * | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
CN110944719A (zh) * | 2017-07-25 | 2020-03-31 | 合帕吉恩治疗公司 | 凋亡蛋白的二聚肽抑制剂 |
CN117130035A (zh) * | 2017-08-18 | 2023-11-28 | 南京中硼联康医疗科技有限公司 | 生物剂量计及具有其的中子捕获治疗系统 |
WO2019180627A1 (en) * | 2018-03-21 | 2019-09-26 | Piramal Enterprises Limited | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES |
CN112533898A (zh) | 2018-07-31 | 2021-03-19 | 日商泛美克斯股份有限公司 | 杂环化合物 |
EP3886909A4 (en) * | 2018-11-29 | 2023-03-29 | Comera Life Sciences, Inc. | ADDITOR COMPOUNDS FOR PROTEIN PROCESSING |
KR20220012844A (ko) * | 2019-04-05 | 2022-02-04 | 헤파진 테라퓨틱스 (에이치케이) 리미티드 | 아포토시스 단백질 억제제의 2가 길항제 |
WO2020223403A1 (en) * | 2019-04-29 | 2020-11-05 | The Regents Of The University Of California | Anticancer smac derivatives |
JPWO2021020585A1 (US08039623-20111018-C00020.png) | 2019-07-31 | 2021-02-04 | ||
EP4093394A1 (en) | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2022198196A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
WO2023127331A1 (ja) * | 2021-12-27 | 2023-07-06 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、除去剤、及びベンジル化合物 |
JP7260725B1 (ja) * | 2021-12-27 | 2023-04-18 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、及び除去剤 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US89896A (en) * | 1869-05-11 | Improvement in bee-hive | ||
US211627A (en) * | 1879-01-28 | Improvement in perforating-stamps | ||
US93428A (en) * | 1869-08-10 | Improvement in spurs for excelsior-machines | ||
US219140A (en) * | 1879-09-02 | Improvement in the art of ornamenting metallic foils | ||
US194741A (en) * | 1877-08-28 | Improvement in circular looms | ||
US25347A (en) * | 1859-09-06 | Improvement | ||
US207525A (en) * | 1878-08-27 | Improvement in car-coupling draw-bars | ||
US180828A (en) * | 1876-08-08 | Improvement in horse-powers | ||
US69812A (en) * | 1867-10-15 | Improved refrigerator | ||
US93429A (en) * | 1869-08-10 | Improvement in flasks for vulcanizing rubber plates for setting teeth | ||
US32437A (en) * | 1861-05-28 | Improvement in steam-plows | ||
US258581A (en) * | 1882-05-30 | husset | ||
JPH0680077B2 (ja) | 1985-02-08 | 1994-10-12 | サントリー株式会社 | プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物 |
JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
AUPN727595A0 (en) * | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
JP4208299B2 (ja) | 1998-08-19 | 2009-01-14 | 東レ株式会社 | 金属板貼合わせ成形加工用ポリエステルフィルム |
US6110691A (en) * | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
WO2002026775A2 (en) | 2000-09-29 | 2002-04-04 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
JP2004536079A (ja) * | 2001-05-16 | 2004-12-02 | アンテックスファーマ・インコーポレーテッド | 置換1−ベンズアゼピンおよびその誘導体 |
MXPA03010762A (es) | 2001-05-31 | 2005-03-07 | Univ Princeton | Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap. |
AU2002314165B2 (en) * | 2001-06-19 | 2008-02-21 | Altana Pharma Ag | Tryptase inhibitors |
US20060258581A1 (en) | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
US20060128632A1 (en) * | 2002-07-02 | 2006-06-15 | Sharma Sushil K | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
DE60324964D1 (de) | 2002-07-15 | 2009-01-08 | Univ Princeton | Iap-bindende verbindungen |
FR2844271A1 (fr) * | 2002-09-09 | 2004-03-12 | Oreal | Derives bis-paraphenylenediamine a groupement pyrrolidinyle et utilisation de ces derives pour la coloration de fibres keratiniques |
WO2004050895A2 (en) * | 2002-11-27 | 2004-06-17 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
US20040180828A1 (en) | 2003-01-30 | 2004-09-16 | Yigong Shi | Caspase-9 : BIR domain of XIAP complexes and methods of use |
AU2004291936A1 (en) * | 2003-11-13 | 2005-06-02 | Burnham Institute | Compositions and methods for screening pro-apoptotic compounds |
CN1933847A (zh) | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
KR20060126548A (ko) | 2004-02-05 | 2006-12-07 | 노파르티스 아게 | (a) DNA 토포이소머라제 억제제 및 (b) IAP 억제제조합물 |
JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 2量体小分子アポトーシス増強剤 |
AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
CA2560162C (en) | 2004-04-07 | 2013-05-21 | Novartis Ag | Inhibitors of iap |
US7244851B2 (en) * | 2004-07-02 | 2007-07-17 | Genentech, Inc. | Inhibitors of IAP |
WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
CA2573644A1 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
WO2006020060A2 (en) * | 2004-07-15 | 2006-02-23 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
AU2006216450C1 (en) * | 2005-02-25 | 2013-01-10 | Medivir Ab | Dimeric IAP inhibitors |
US20070003535A1 (en) | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
DE102005017116A1 (de) | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
EP1888619B1 (en) | 2005-05-25 | 2013-04-17 | 2cureX ApS | Compounds modifying apoptosis |
BRPI0611922A2 (pt) | 2005-06-08 | 2010-10-05 | Novartis Ag | compostos orgánicos |
CA2617642A1 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
EP1973899A4 (en) | 2005-12-19 | 2010-10-20 | Genentech Inc | HEMMER OF IAP |
CA2632256A1 (en) | 2005-12-20 | 2007-07-05 | Novartis Ag | Combination of an iap-inhibitor and a taxane7 |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
JP2009530424A (ja) | 2006-03-21 | 2009-08-27 | ジョイアント ファーマスーティカルズ、インク. | 小分子アポトーシスプロモーター |
JP5230610B2 (ja) | 2006-05-05 | 2013-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 二価smac模倣物およびその使用 |
MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
US20100113326A1 (en) | 2006-07-24 | 2010-05-06 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100143499A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Iap阻害剤 |
US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
CL2007002167A1 (es) | 2006-07-24 | 2009-01-23 | Tetralogic Pharm Corp | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. |
US20100144650A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
PE20080951A1 (es) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
BRPI0719221A2 (pt) | 2006-10-12 | 2014-03-18 | Novartis Ag | Derivados de pirrolidina como inibidores de iap |
JP2010507096A (ja) | 2006-10-19 | 2010-03-04 | ノバルティス アーゲー | 有機化合物 |
WO2008067280A2 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Combination of iap inhibitors and flt3 inhibitors |
WO2008085610A1 (en) | 2006-11-28 | 2008-07-17 | Novartis Ag | Use of iap inhibitors for the treatment of acute myeloid leukemia |
CA2670728A1 (en) | 2006-12-07 | 2008-06-19 | Novartis Ag | Pyridine derivatives used as xiap inhibitors |
KR20090094461A (ko) | 2006-12-19 | 2009-09-07 | 제넨테크, 인크. | Iap의 이미다조피리딘 억제제 |
AU2008240153B2 (en) | 2007-04-12 | 2013-01-31 | Joyant Pharmaceuticals, Inc. | SMAC mimetic dimers and trimers useful as anti-cancer agents |
PL2139490T3 (pl) | 2007-04-13 | 2014-11-28 | Univ Michigan Regents | Diazobicykliczne mimetyki Smac i ich zastosowania |
WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
US20100203012A1 (en) | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
-
2007
- 2007-03-15 TW TW096108935A patent/TWI504597B/zh not_active IP Right Cessation
- 2007-03-15 TW TW103145747A patent/TWI543988B/zh not_active IP Right Cessation
- 2007-03-16 CA CA2581960A patent/CA2581960C/en not_active Expired - Fee Related
- 2007-03-16 AU AU2007224932A patent/AU2007224932B2/en not_active Ceased
- 2007-03-16 WO PCT/CA2007/000428 patent/WO2007104162A1/en active Application Filing
- 2007-03-16 BR BRPI0709610-0A patent/BRPI0709610A2/pt not_active IP Right Cessation
- 2007-03-16 MX MX2008011837A patent/MX2008011837A/es active IP Right Grant
- 2007-03-16 JP JP2008558611A patent/JP5419468B2/ja not_active Expired - Fee Related
- 2007-03-16 US US11/723,044 patent/US7579320B2/en not_active Expired - Fee Related
- 2007-03-16 KR KR1020087025218A patent/KR101446907B1/ko not_active IP Right Cessation
- 2007-03-16 SG SG201101952-8A patent/SG170739A1/en unknown
- 2007-03-16 NZ NZ571577A patent/NZ571577A/en not_active IP Right Cessation
- 2007-03-16 EP EP07710756A patent/EP2004600A4/en not_active Withdrawn
- 2007-11-01 US US11/979,280 patent/US7645741B2/en not_active Expired - Fee Related
-
2008
- 2008-09-07 IL IL193951A patent/IL193951A/en not_active IP Right Cessation
- 2008-09-09 NO NO20083868A patent/NO20083868L/no not_active Application Discontinuation
-
2009
- 2009-11-17 US US12/619,979 patent/US20100221261A1/en not_active Abandoned
-
2012
- 2012-11-08 US US13/672,637 patent/US8765681B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 US US14/285,841 patent/US9365614B2/en not_active Expired - Fee Related
- 2014-10-28 PH PH12014502420A patent/PH12014502420A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP5419468B2 (ja) | 2014-02-19 |
US20100221261A1 (en) | 2010-09-02 |
EP2004600A1 (en) | 2008-12-24 |
TW201538520A (zh) | 2015-10-16 |
JP2009529544A (ja) | 2009-08-20 |
TWI504597B (zh) | 2015-10-21 |
BRPI0709610A2 (pt) | 2011-07-19 |
CA2581960A1 (en) | 2007-09-16 |
KR20080112304A (ko) | 2008-12-24 |
TWI543988B (zh) | 2016-08-01 |
PH12014502420B1 (en) | 2015-11-16 |
IL193951A (en) | 2015-09-24 |
RU2008140935A (ru) | 2010-04-27 |
US20080069812A1 (en) | 2008-03-20 |
NZ571577A (en) | 2011-09-30 |
SG170739A1 (en) | 2011-05-30 |
PH12014502420A1 (en) | 2015-11-16 |
US7645741B2 (en) | 2010-01-12 |
US9365614B2 (en) | 2016-06-14 |
US8765681B2 (en) | 2014-07-01 |
AU2007224932B2 (en) | 2013-05-23 |
US20140336134A1 (en) | 2014-11-13 |
CA2581960C (en) | 2015-11-24 |
KR101446907B1 (ko) | 2014-10-06 |
MX2008011837A (es) | 2009-02-10 |
US20080207525A1 (en) | 2008-08-28 |
US7579320B2 (en) | 2009-08-25 |
AU2007224932A1 (en) | 2007-09-20 |
WO2007104162A1 (en) | 2007-09-20 |
EP2004600A4 (en) | 2012-05-02 |
US20130071411A1 (en) | 2013-03-21 |
TW200800961A (en) | 2008-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083868L (no) | IAP BIR domenebindende forbindelser | |
SMT201300085B (it) | Composti di pirrolo | |
WO2008108380A3 (en) | Pyrrole compounds | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
TW200833675A (en) | Nicotinamide derivatives | |
NO20082338L (no) | Pyrimidinderivater for behandling av avvikende cellevekst | |
WO2008057775A3 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
EA201171000A1 (ru) | Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии | |
EA200700758A1 (ru) | Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
TW200710084A (en) | Process for the synthesis of organic compounds | |
WO2007081690A3 (en) | Inhibitors of protein kinases | |
DK1745010T3 (da) | Substituerede cyklohexyl-1,4-diaminderivater | |
ATE488510T1 (de) | Heterocyclische derivate, deren herstellung und therapeutische verwendung | |
EA200801123A1 (ru) | Производные 6-гетероарилпиридоиндолона, способ их получения и применение их в терапии | |
MY137964A (en) | Benzofuran derivative | |
EA201001252A1 (ru) | Способ получения производных 3,6-дигидро-1,3,5-триазина | |
NO20062307L (no) | Spirofuropyridinarylderivater | |
DE60108089D1 (de) | Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel | |
EA200401432A1 (ru) | Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков | |
EA200601248A1 (ru) | Новые многократно замещённые соединения 1,1-пиридилоксициклопропанамина, способ их получения и фармацевтические композиции, которые их содержат | |
NO20064410L (no) | Fremgangsmate for fremstilling av tryptaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: PHARMASCIENCE INC, CA |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |